Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
dmPFC-vlPAG projection neurons contribute to pain threshold maintenance and antianxiety behaviors
Jun-Bin Yin, … , Yu-Lin Dong, Yun-Qing Li
Jun-Bin Yin, … , Yu-Lin Dong, Yun-Qing Li
Published August 25, 2020
Citation Information: J Clin Invest. 2020;130(12):6555-6570. https://doi.org/10.1172/JCI127607.
View: Text | PDF
Research Article Neuroscience

dmPFC-vlPAG projection neurons contribute to pain threshold maintenance and antianxiety behaviors

  • Text
  • PDF
Abstract

The dorsal medial prefrontal cortex (dmPFC) has been recognized as a key cortical area for nociceptive modulation. However, the underlying neural pathway and the function of specific cell types remain largely unclear. Here, we show that lesions in the dmPFC induced an algesic and anxious state. Using multiple tracing methods including a rabies-based transsynaptic tracing method, we outlined an excitatory descending neural pathway from the dmPFC to the ventrolateral periaqueductal gray (vlPAG). Specific activation of the dmPFC/vlPAG neural pathway by optogenetic manipulation produced analgesic and antianxiety effects in a mouse model of chronic pain. Inhibitory neurons in the dmPFC were specifically activated using a chemogenetic approach, which logically produced an algesic and anxious state under both normal and chronic pain conditions. Antagonists of the GABAA receptor (GABAAR) or mGluR1 were applied to the dmPFC, which produced analgesic and antianxiety effects. In summary, the results of our study suggest that the dmPFC/vlPAG neural pathway might participate in the maintenance of pain thresholds and antianxiety behaviors under normal conditions, while silencing or suppressing the dmPFC/vlPAG pathway might be involved in the initial stages and maintenance of chronic pain and the emergence of anxiety-like behaviors.

Authors

Jun-Bin Yin, Shao-Hua Liang, Fei Li, Wen-Jun Zhao, Yang Bai, Yi Sun, Zhen-Yu Wu, Tan Ding, Yan Sun, Hai-Xia Liu, Ya-Cheng Lu, Ting Zhang, Jing Huang, Tao Chen, Hui Li, Zhou-Feng Chen, Jing Cao, Rui Ren, Ya-Nan Peng, Juan Yang, Wei-Dong Zang, Xiang Li, Yu-Lin Dong, Yun-Qing Li

×

Figure 1

Bilateral lesions in the dmPFC worsen CPNL-induced mechanical nociception and anxiety-like behaviors.

Options: View larger image (or click on image) Download as PowerPoint
Bilateral lesions in the dmPFC worsen CPNL-induced mechanical nociceptio...
(A and B) Representative schematic diagrams of the KA injection into the dmPFC and procedures for the behavioral tests. PWT, paw withdrawal threshold. (C) Nissl staining of the dmPFC after KA or saline dmPFC injections. Scale bar: 200 μm. (D) Mechanical thresholds at baseline and 7 days after saline or KA dmPFC injections. **P < 0.01, by paired t test (n = 5). Mechanical thresholds of the ipsilateral (E) and contralateral (F) hind paws following CPNL with saline or KA dmPFC injections (E: F( 1, 32) = 6.07, P =0.04; &P < 0.05; F: F( 1, 32)= 4.22, P = 0.07; *P < 0.05; 2-way, repeated-measures ANOVA with Bonferroni’s post hoc test (n = 5). (G) Responses to non-nociceptive stimulation at baseline and 7 days after saline or KA dmPFC injections (n = 5). Responses to non-nociceptive stimulation of the ipsilateral (H) and contralateral (I) hind paws following CPNL with saline or KA dmPFC injections (H : F(1, 32) = 9.80, P = 0.014; &P < 0.05 ; I: F(1, 32) = 10.68, P = 0.011; &P < 0.05; 2-way, repeated-measures ANOVA with Bonferroni’s post hoc test, *P < 0.05, **P < 0.01 (n = 5). (J) Schematic traces of the OF and EPM tests at baseline, 7 days after KA injection, and 7 days after KA injection plus 14 days after CPNL. Total distance traveled (K) and percentage of time spent in the central area (L) in the OF test (saline injection, K: F(2, 8) = 0.11, P = 0.90; L: F(2, 8) = 5.97, P = 0.03; KA injection, K: F(2, 8) = 24.97, P < 0.001; L: F(2, 8) = 9.33, P < 0.01; 1-way, repeated-measures ANOVA with Tukey’s post hoc test, *P < 0.05, **P < 0.01, and ***P < 0.001; $P < 0.05 and $$P < 0.01; #P < 0.05 (n = 5). Percentage of time in (M) and percentage of entries into (N) the OAs in the EPM test (saline injection, M: F(2, 8) = 13.22, P < 0.01; N: F(2, 8) = 20.28, P < 0.001; KA injection, M: F(2, 8) = 17.34, P < 0.01; N: F(2, 8) = 23.23, P < 0.001; 1-way, repeated measures ANOVA with Tukey’s post hoc test, **P < 0.01 and ***P < 0.001; $$P < 0.01; ##P < 0.01 (n = 5).

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts